Latest Breaking News On - Phase 3 atlas trial - Page 1 : comparemela.com

Treatment with UGN-102 with or without transurethral resection of bladder tumors led to an improvement in disease-free survival compared with TURBT alone in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.

United statesNew jerseyUrogen pharmaSandip prasadLiz barrettGenitourinary surgical oncologyMorristown medicalAtlantic health systemUrothelial cancerNon muscle invasive bladder cancerUgn 102 mitomycinTransurethral resectionPhase 3 atlas trialPhase 3 envision trial